These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20080917)

  • 1. Azathioprine: association with therapy-related myelodysplastic syndrome and acute myeloid leukemia.
    Kwong YL
    J Rheumatol; 2010 Mar; 37(3):485-90. PubMed ID: 20080917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Ogasawara T; Yasuyama M; Kawauchi K
    Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7.
    Knipp S; Hildebrandt B; Richter J; Haas R; Germing U; Gattermann N
    Haematologica; 2005 May; 90(5):691-3. PubMed ID: 15921387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
    Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
    Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
    Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
    Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
    Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses.
    Ibrahim S; Estey EH; Pierce S; Glassman A; Keating M; O'Brien S; Kantarjian HM; Albitar M
    Am J Clin Pathol; 2000 Nov; 114(5):793-7. PubMed ID: 11068555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Abnormalities of chromosome 17 in myeloid malignancies with complex chromosomal abnormalities].
    Zhu Y; Xu W; Liu Q; Pan J; Qiu H; Wang R; Qiao C; Jiang Y; Zhang S; Fan L; Zhang J; Shen Y; Xue Y; Li J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):579-82. PubMed ID: 18841577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
    J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
    Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J
    Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translocation (3;8)(q26;q24): a recurrent chromosomal abnormality in myelodysplastic syndrome and acute myeloid leukemia.
    Lin P; Medeiros LJ; Yin CC; Abruzzo LV
    Cancer Genet Cytogenet; 2006 Apr; 166(1):82-5. PubMed ID: 16616115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
    Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features.
    Au WY; Lam CC; Ma ES; Man C; Wan T; Kwong YL
    Hum Pathol; 2001 Jan; 32(1):126-9. PubMed ID: 11172306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; De Braekeleer M
    Eur J Haematol; 2007 Jun; 78(6):457-67. PubMed ID: 17391336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.
    Estey E; Trujillo JM; Cork A; O'Brien S; Beran M; Kantarjian H; Keating M; Freireich EJ; Stass S
    Hematol Pathol; 1992; 6(1):43-8. PubMed ID: 1601822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease.
    McCarthy CJ; Sheldon S; Ross CW; McCune WJ
    Arthritis Rheum; 1998 Aug; 41(8):1493-6. PubMed ID: 9704650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.